Voyager Therapeutics announces data from SAD trial of VY7523
Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational ...
Voyager reports promising data for early stage trial in Alzheimer’s disease treatment
Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...
Business Insider1mon
Positive Outlook for Voyager Therapeutics Driven by Promising CNS Gene Therapies and Innovative TRACER Platform
The company is advancing multiple programs, such as VY7523 and VY1706, which are focused on addressing neurodegenerative diseases like Alzheimer’s and ALS. These programs are nearing important ...